Experiment 1072289

Details

PropertyValue
Pharmacology
Administration routeIV
OrganismMaytenus buchananii (CELASTRACEAE)
CitationCREAGEN,ET: FLEMING,TR: EDMONSON,JH: INGLE,JN:. (1979). PHASE II EVALUATION OF MAYTANSINE IN PATIENTS WITH ADVANCED HEAD AND NECK CANCER.. 63()
Amount utilized
Compound isolated
DiseaseA PHASE II STUDY 31 PATIENTS WITH MEASURABLE OR EVALUABLE ADVANCED HEAD AND NECK CANCER(MEDIAN AGE = 62) DOSING WAS FOR 3 CONSECUTIVE DAYS WITH THE FIRST RETREATMENT 3 WEEKS LATER AND SUBSEQUENT RETREATMENTS AT 4-WEEK INTERVALS TOXICITY WAS MAINLY GASTROINTESTINAL:MODERATE TO SEVERE NAUSEA AND VOMITING OCCURRED IN 6/31 PATIENTS DIARRHEA WAS MODERATE TO SEVERE IN 5/31 PATIENTS. ONLY 1/31(3%),PATIENTS HAD GREATER THAN A 50% OBJECTIVE RESPONSE CONCLUSION:MAYTANSINE WAS NOT RECOMMENDED FOR FURTHER STUDY IN HEAD AND NECK CANCER
Dose amount0.6 MG
Number2
Qualitative resultACTIVE
AnimalHUMAN ADULT
Per unitSQ M BODY SURFACE
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES